Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study
Compared with TACE plus lenvatinib, triple therapy with TACE, lenvatinib, and PD-1 inhibitor resulted in better PFS and OS. These findings support the consideration of this triple combination as a promising first-line treatment option for unresectable huge HCC and warrant further validation in prospective studies.
Authors
- Ruixia Li (ORCID: https://orcid.org/0000-0002-0179-1807)
- Wenle Tan (ORCID: https://orcid.org/0000-0001-5933-2833)
- Feng Duan (ORCID: https://orcid.org/0000-0001-8432-590X)
- Ren Yuan
- Qunfang Zhou (ORCID: https://orcid.org/0000-0003-2521-100X)
- Mingyu Liu (ORCID: https://orcid.org/0000-0003-0940-8953)
- Xiaohui Li (ORCID: https://orcid.org/0000-0002-7149-0532)
- H. J. Yang (ORCID: https://orcid.org/0009-0004-8274-9863)
- Liang Ye (ORCID: https://orcid.org/0000-0002-7047-4450)
- Hui Li (ORCID: https://orcid.org/0000-0001-6841-2229)
- Xiaohui Wang (ORCID: https://orcid.org/0000-0001-8355-3871)
- Junxia Wu (ORCID: https://orcid.org/0000-0002-3620-959X)
Institutions
- Sun Yat-sen University (CN)
- Chinese PLA General Hospital (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hunan Provincial People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1097/js9.0000000000004131
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64